MicroRNAs: Novel Biomarkers for Human Cancer
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Background: MicroRNAs (miRNAs), small RNA molecules of approximately 22 nucleotides, have been shown to be up- or downregulated in specific cell types and disease states. These molecules have become recognized as one of the major regulatory gatekeepers of coding genes in the human genome. Content: We review the structure, nomenclature, mechanism of action, technologies used for miRNA detection, and associations of miRNAs with human cancer. miRNAs are produced in a tissue-specific manner, and changes in miRNA within a tissue type can be correlated with disease status. miRNAs appear to regulate mRNA translation and degradation via mechanisms that are dependent on the degree of complementarity between the miRNA and mRNA molecules. miRNAs can be detected via several methods, such as microarrays, bead-based arrays, and quantitative real-time PCR. The tissue concentrations of specific miRNAs have been associated with tumor invasiveness, metastatic potential, and other clinical characteristics for several types of cancers, including chronic lymphocytic leukemia, and breast, colorectal, hepatic, lung, pancreatic, and prostate cancers. Summary: By targeting and controlling the expression of mRNA, miRNAs can control highly complex signal-transduction pathways and other biological pathways. The biologic roles of miRNAs in cancer suggest a correlation with prognosis and therapeutic outcome. Further investigation of these roles may lead to new approaches for the categorization, diagnosis, and treatment of human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
The nuclear RNase III Drosha initiates microRNA processing
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Rådmark, O., Kim, S., et al. (2003) · Nature · doi:10.1038/nature01957 · Cited by 5,114
MicroRNA genes are transcribed by RNA polymerase II
Lee, Y., Kim, M., Han, J., Yeom, K., Lee, S., Baek, S. H., & Kim, V. N. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600385 · Cited by 4,373
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
miRBase: microRNA sequences, targets and gene nomenclature
Griffiths-Jones, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj112 · Cited by 3,950
RAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
The Microprocessor complex mediates the genesis of microRNAs
Gregory, R. I., Yan, K.-P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., & Shiekhattar, R. (2004) · Nature · doi:10.1038/nature03120 · Cited by 2,742
Cited by
Schmidt, L. H., Spieker, T., Koschmieder, S., Humberg, J., Jungen, D., Bulk, E., Hascher, A., Wittmer, D., Marra, A., Hillejan, L., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307eac · Cited by 545
Exosome mimetics: a novel class of drug delivery systems
Schiffelers, R., Kooijmans, S., Vader, van Dommelen, & Solinge, V. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29661 · Cited by 512
Genomic Medicine — An Updated Primer
Feero, W. G., Guttmacher, A. E., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0907175 · Cited by 442
Plasma MicroRNA-122 as a Biomarker for Viral-, Alcohol-, and Chemical-Related Hepatic Diseases
Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., Fei, M., & Sun, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147850 · Cited by 415
Clinical Outcomes and Correlates of TP53 Mutations and Cancer
Robles, A. I., & Harris, C. C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001016 · Cited by 394
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Ji, Q., Zhang, L., Liu, X., Zhou, L., Wang, W., Han, Z., Sui, H., Tang, Y., Wang, Y., Liu, N., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.383 · Cited by 381
Akhtar, N., Rasheed, Z., Ramamurthy, S., Anbazhagan, A. N., Voss, F. R., & Haqqi, T. M. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27329 · Cited by 331
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring
McGuire, A., Brown, J. A. L., & Kerin, M. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9551-7 · Cited by 329
Catalytic Molecular Imaging of MicroRNA in Living Cells by DNA‐Programmed Nanoparticle Disassembly
He, X., Zeng, T., Li, Z., Wang, G., & Ma, N. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201509726 · Cited by 291
Human Traumatic Brain Injury Alters Plasma microRNA Levels
Redell, J. B., Moore, A. N., Ward, N. H., Hergenroeder, G. W., & Dash, P. K. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2010.1481 · Cited by 282
Silva, J., García, V., Zaballos, Á., Provencio, M., Lombardía, L., Almonacid, L., García, J. M., Domínguez, G., Peña, C., Diaz, R., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00029610 · Cited by 280
Identification of blood microRNAs associated to Parkinsońs disease
Margis, R., Margis, R., & Rieder, C. R. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.01.023 · Cited by 263
“Indeed, microRNAs have been used as molecular markers in a series of diseases, including cancer, neurodegenerative disorders and others (Bartels and Tsongalis, 2009; Nelson et al., 2008; Pauley et al., 2009).”
BackgroundNalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024099 · Cited by 256
Cancer Biomarkers: Are We Ready for the Prime Time?
Mishra, A., & Verma, M. (2010) · Cancers · doi:10.3390/cancers2010190 · Cited by 236
“The expression of specific populations of miRNA in a tissue- and time-dependent manner is associated with clinical characteristics for several cancer types, such as leukemia, breast, prostate, colorectal, hepatic, lung, and pancreatic cancers [39–41].”
BackgroundIn Situ Amplification‐Based Imaging of RNA in Living Cells
Qing, Z., Xu, J., Hu, J., Zheng, J., He, L., Zou, Z., Yang, S., Tan, W., & Yang, R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812449 · Cited by 215
Predictive and prognostic molecular markers for cancer medicine
Mehta, S., Shelling, A., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G., & Print, C. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009360519 · Cited by 210
“All of this raises the exciting prospect that ncRNAs may in the future provide clinically-useful biomarkers for cancer prognostication [Bartels and Tsongalis, 2009].”
BackgroundMicroRNA Detection: Current Technology and Research Strategies
Hunt, E. A., Broyles, D., Head, T., & Deo, S. K. (2015) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-071114-040343 · Cited by 190
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
Zhou, Y., Chen, L., Barlogie, B., Stephens, O., Wu, X., Williams, D. R., Cartron, M.-A., van Rhee, F., Nair, B., Waheed, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908441107 · Cited by 190
“Global increases in miRNA expression were seen in cases with high-risk MM, which sharply contrasts with discriminate expression changes of only selected miRNAs that are seen in other cancers (4, 5, 15).”
BackgroundCirculating tumor cells: advances in detection methods, biological issues, and clinical relevance
Sun, Y.-F., Yang, X.-R., Zhou, J., Qiu, S.-J., Fan, J., & Xu, Y. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-0988-y · Cited by 184
“(Bartels and Tsongalis 2009) Hence, miRNA-based gene therapy offers a novel anticancer strategy, making the profiling of miRNA in CTCs even more appealing.”
BackgroundLoss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers
Cochrane, D. R., Howe, E. N., Spoelstra, N. S., & Richer, J. K. (2010) · Journal of Oncology · doi:10.1155/2010/821717 · Cited by 162
MicroRNA-23a promotes myelination in the central nervous system
Lin, S.-T., Huang, Y., Zhang, L., Heng, M. Y., Ptáček, L. J., & Fu, Y.-H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317182110 · Cited by 117
“miRNAs bind to the coding sequences or 3′-UTRs of target transcripts, thus leading to impaired translation or increased degradation of transcripts (33).”
miR‐144‐5p enhances the Radiosensitivity of non‐small‐cell lung Cancer cells via targeting ATF2
Song, L., Peng, L., Hua, S., Li, X., Ma, L., Jie, J., Chen, D., Wang, Y., & Li, D. (2018) · BioMed Research International · doi:10.1155/2018/5109497 · Cited by 93
Szeto, C.-C., & Li, P. K.-T. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.50 · Cited by 80
A microRNA Signature Associated with Early Recurrence in Breast Cancer
Pérez-Rivas, L. G., Jerez, J. M., Carmona, R., de Luque, V., Vicioso, L., Claros, M. G., Viguera, E., Pajares, B., Sánchez, A., Ribelles, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091884 · Cited by 67
Garavelli, S., Bruzzaniti, S., Tagliabue, E., Di Silvestre, D., Prattichizzo, F., Mozzillo, E., Fattorusso, V., La Sala, L., Ceriello, A., Puca, A. A., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05237-x · Cited by 37
Metadata
- Authors
- Bartels, C. L., & Tsongalis, G. J.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-01
- Volume
- 55
- Issue
- 4
- Pages
- 623-631
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W1969362786
- Cited by
- 529
- References
- 76
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.